Short Interest in BioLineRx Ltd. (NASDAQ:BLRX) Increases By 76.1%

BioLineRx Ltd. (NASDAQ:BLRX) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 216,400 shares, a growth of 76.1% from the January 31st total of 122,900 shares. Based on an average trading volume of 219,300 shares, the short-interest ratio is presently 1.0 days. Currently, 5.9% of the company’s stock are sold short.

BioLineRx Stock Performance

NASDAQ BLRX opened at $3.16 on Tuesday. BioLineRx has a 1 year low of $3.11 and a 1 year high of $57.20. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.37. The stock has a market capitalization of $10.52 million, a PE ratio of -0.36 and a beta of 1.41. The company’s 50 day simple moving average is $5.06 and its two-hundred day simple moving average is $14.11.

Institutional Trading of BioLineRx

An institutional investor recently raised its position in BioLineRx stock. Atria Investments Inc grew its stake in shares of BioLineRx Ltd. (NASDAQ:BLRX) by 27.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 133,974 shares of the biotechnology company’s stock after buying an additional 29,193 shares during the quarter. Atria Investments Inc owned 0.17% of BioLineRx worth $72,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 1.56% of the company’s stock.

Analysts Set New Price Targets

BLRX has been the subject of a number of research reports. HC Wainwright reduced their target price on shares of BioLineRx from $840.00 to $360.00 and set a “buy” rating for the company in a research report on Monday, November 25th. StockNews.com initiated coverage on shares of BioLineRx in a research note on Tuesday, February 4th. They set a “hold” rating on the stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.